knowledge -WSS

knowledge

author：focus 2025-09-27 19:28:34 - browse：55

Enticed by the immense market opened by GLP-1 weight loss drugs Wegovy and Zepbound, a handful of biotech companies are trying to develop next-generation, longer-lasting therapies based on a very different approach: RNA interference.

This Nobel Prize-winning science works by degrading the biological blueprints that RNA use to make proteins — without the genetic instructions, the troublesome proteins are never made and the gene is essentially muted.

If the companies succeed, it would be a significant shift in the obesity treatment revolution, away from weekly drugs targeting hormones to medications that could be given much less frequently — twice a year or even less — and pinpoint genetic contributors to weight.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： UnitedHealth CEO's Medicaid comments send insurer stocks diving

explore

WSS

Community addresses injustice for Long Island mothers

Pfizer's Covid pill remains 89% effective in final analysis, company says

These geoengineering technologies could help combat the climate crisis, scientists say

Doctor appointment wait times are getting worse

RaDonda Vaught case: a double standard for nurses, physicians

'Little Tech' descents on D.C., wanting a say in how AI is regulated

entertainment

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

23andMe had bad news about my health. I wish a person had delivered it

Senators tussle over abortion against the backdrop of a presidential campaign

Heart attack and stroke risk calculators need revising

Stopping antidepressants leads to symptoms for 1 in 6 patients

Duchenne breakthrough therapy leaves behind pioneering families

Medicare Advantage's lean provider networks lead CMS complaints

In Memoriam: Notable people who died in 2023

Grail is spending more than ever lobbying Congress

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

4 killed, 7 hurt in mass shooting at July 4 block party in Louisiana; no arrests made

knowledge

Bacterial infection may be ‘key event’ in endometriosis, study says

Listen: Biogen's messy board & Laronde's data problem

How CO2 helps viruses stay alive longer in the air

Community addresses injustice for Long Island mothers

Make 'food is medicine' a key part of White House nutrition meeting

Make 'food is medicine' a key part of White House nutrition meeting

hotspot

explore

hotspot

explore